Previous 10 | Next 10 |
Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...
SARASOTA, Fla. and NOVATO, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that GeneTx...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this Read more ...
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
Ultragenyx Pharmaceutical (NASDAQ: RARE ) preliminary full-year 2019 total revenue of $102M-$104M exceeds the average analyst estimate of $100.0M. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
Ultragenyx (NASDAQ: RARE ) and collaboration partner Kyowa Kirin ( OTCPK:KYKOF ) announce the filing of a supplemental marketing application in the U.S. seeking approval to use Crysvita (burosumab) to treat FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tum...
Preliminary 2019 total revenue is approximately $102 million to $104 million Preliminary 2019 Crysvita revenue to Ultragenyx of approximately $86 million to $88 million 2020 Crysvita revenue in Ultragenyx territories is expected to be in the range of $125 million to $140 million e...
NOVATO, Calif. and TOKYO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) today announced...
After disclosing the latest data for its gene therapy DTX301 in ornithine transcarbamylase (OTC) deficiency, Ultragenyx Pharmaceutical (NASDAQ: RARE) saw its shares gain 13.4% on Friday. Ultragenyx is a biotech stock focused on developing new treatments for rare dise...
Gainers: Sorrento Therapeutics (NASDAQ: SRNE ) +38% . More news on: Sorrento Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., Venus Concept Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...